BXQ-350 Neuroprotective Outcomes in Chemotherapy Induced Peripheral Neuropathy (CIPN) Patients
from Bexionpharma.com During Bexion’s Phase 1 study of BXQ-350 in adult patients with advanced solid tumors, a patient self-reported complete resolution of long term, persistent Chemotherapy Induced Peripheral Neuropathy (CIPN). Due to this unexpected reporting, Bexion elected to explore this finding further by reviewing data from a cohort of patients…